ANIP 54.33 ANI Pharmaceuticals Inc $ANIP Hit a 52 week high

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
ANIP 54.33 ANI Pharmaceuticals Inc $ANIP Hit a 52 week high of 54.32 Closing the day 09:44 at 54.33 +1.46 +2.76% With a day low of 52.94 and a total volume of 12,313.

ANIP Recent Posts: http://investorshangout.com/ANI-Pharmaceutica...NIP-53540/

ANIP ANI Pharmaceuticals Inc Recent Headline News

Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Soars 17.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 56 mins ago
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14), FOLD: 6.42 (-0.28)

Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape
Vaishali Doshi Shah - Zacks Investment Research - 59 mins ago
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as the company saw its shares rise by almost 29% on the day.
ANIP: 54.35 (+1.48), CLDX: 17.48 (-0.77), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14)

Integra (IART) Strengthens Spinal Implant with Twin Launches - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 2:30PM CST
The latest Interbody and orthobiologic device launches are expected to drive a sequential increase in Integra Lifesciences' (IART) spine sales in the fourth quarter of 2014.
IART: 48.09 (+0.57), ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14)

Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:42AM CST
Kite Pharma, Inc. (KITE) reported third-quarter 2014 loss of $0.24 per share well below the year-ago loss of $37 cents per share.
BIIB: 305.43 (+3.01), KITE: 40.34 (+0.04), ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06)

Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:45AM CST
Puma Biotechnology has been witnessing a negative trend in its current year loss estimates and its share price falling for past few weeks
ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14), PBYI: 216.59 (+5.04)

Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 305.43 (+3.01), ANIP: 54.35 (+1.48), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14)

Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 54.35 (+1.48), ICPT: 159.61 (+1.51), AMAG: 35.82 (+1.06), AFFX: 9.43 (+0.14)

Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:26AM CST
Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue?
ANIP: 54.35 (+1.48)

ANI Pharma (ANIP) & Sucampo Pharma (SCMP): Top Momentum Stocks to Add to Your Portfolio - Video Blog
David Bartosiak - Zacks Investment Research - Wed Nov 12, 1:59PM CST
ANI Pharma (ANIP) & Sucampo Pharma (SCMP), this week's top momentum stocks are discussed by Momentum Strategist David Bartosiak.
ANIP: 54.35 (+1.48), SCMP: 12.38 (+0.79)

Why ANI Pharmaceuticals (ANIP) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:54AM CST
ANI Pharmaceuticals could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
ANIP: 54.35 (+1.48)

Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 305.43 (+3.01), ANIP: 54.35 (+1.48), CLDX: 17.53 (-0.72), AMAG: 35.82 (+1.06)

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ALLY: 23.69 (+0.22), ANIP: 54.35 (+1.48), ACGL: 57.10 (+0.19), ACCO: 9.00 (+0.03), FLWS: 8.65 (+0.01)

ANI Pharmaceuticals Announces the Launch of Methazolamide Tablets USP
PR Newswire - Thu Nov 06, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI" (NASDAQ: ANIP) today announced the launch of Methazolamide USP 25mg and 50mg oral tablets, indicated for the treatment of ocular conditions. The US market for Methazolamide totals $24 million on a trailing 12 month basis, per IMS Health.
ANIP: 54.35 (+1.48)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
SYKE: 23.43 (+0.32), HBNK: 20.13 (+0.07), ASMI: 41.92 (+0.21), RRGB: 68.05 (+0.60), SAPE: 24.68 (+0.03), PLUG: 3.97 (+0.25), ANIP: 54.35 (+1.48), ODP: 6.73 (+0.04), MTEX: 22.60 (+0.09), JAXB: 11.03 (-0.02), ALQA: 5.09 (+0.13), YRCW: 23.12 (+0.48)

Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST

FRM: 6.34 (+0.22), NEO: 4.63 (+0.03), AU: 9.81 (+0.15), FNHC: 24.76 (+0.63), AMS: 2.53 (unch), NYMX: 0.53 (-0.01), AMDA: 1.33 (-0.02), CVD: 100.79 (+0.33), GBIM: 6.74 (+0.27), RCAP: 12.24 (+0.05), KBIO: 2.02 (+0.03), COOL: 0.75 (-0.01), SAPE: 24.68 (+0.03), XTLB: 2.43 (-0.15), GERN: 3.07 (+0.09), ANIP: 54.35 (+1.48), BBLU: 1.11 (-0.06), NXTD: 2.29 (+0.05), AP: 18.84 (+0.15), ALQA: 5.09 (+0.13)

ANI Pharma ups revenues 123% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 8:21AM CST

ANIP: 54.35 (+1.48)

ANI posts 3Q profit
Automated Insights - Mon Nov 03, 7:46AM CST
BAUDETTE, Minn. (AP) _ ANI Pharmaceuticals Inc. (ANIP) on Monday reported profit of $6.7 million in its third quarter.
ANIP: 54.35 (+1.48)

ANI Pharmaceuticals beats by $0.20, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 7:34AM CST

ANIP: 54.35 (+1.48)

ANI Pharmaceuticals Reports Record Third Quarter 2014 Financial Results and Year-To-Date Highlights
PR Newswire - Mon Nov 03, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI" (NASDAQ: ANIP) today reported financial results for the three and nine months ended September 30, 2014 and increased its revenue and non-GAAP EBITDA guidance for the fourth quarter of 2014.
ANIP: 54.35 (+1.48)

Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 02, 4:30PM CST

ACW: 4.95 (+0.03), SYY: 38.92 (+0.03), L: 42.54 (-0.05), EEP: 38.47 (+0.24), SNH: 22.18 (unch), INN: 11.54 (+0.05), ITG: 19.97 (+0.43), NSP: 32.71 (+0.11), S: 4.80 (-0.11), ALE: 50.30 (+0.21), GVA: 36.05 (+0.34), MCY: 54.36 (+0.22), ARNA: 4.53 (+0.03), CHD: 73.96 (+0.07), ARE: 82.94 (unch), USAK: 18.75 (+0.31), BWP: 16.78 (-0.12), KRG: 26.20 (+0.02), CYOU: 22.55 (unch), MNKD: 6.45 (+0.19), HNT: 51.94 (+0.85), AMH: 17.30 (+0.04), ARCB: 42.20 (-0.13), ANIP: 54.35 (+1.48), AMG: 197.47 (+2.01), HAE: 37.34 (+0.34), SOHU: 49.68 (+0.45), CNA: 39.27 (+0.16)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 136

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 218

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 337

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 288

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 201

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 531

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 161

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 97

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
D-Wave Investors Must Decide by Dec 15 Class Suit

Updated Category News Views 117

Facing the Class Action Deadline There's nothing like a looming deadline to stir the pot, and that's exactly what's happening with D-Wave Quantum Inc. (NASDAQ: QBTS) as it faces the heat of a class action lawsuit. Investors who got caught in the slide between February 26, 2026, and August 25, 2026, need to sharpen their pencils and mark December 15, 2026, on their...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 206

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the Enhanced Features of the New ONYX RX32 Scrubber

Updated Category News Views 116

Introducing the New RX32 Ride-On Floor Scrubber Optimal Performance for Large-Area Cleaning In response to the growing need for effective cleaning solutions, ONYX Systems, LLC launches the advanced RX32 Ride-On Floor Scrubber. This 32-inch scrubber is designed specifically to enhance cleaning efficiency and productivity in large facilities. Unmatched Cleaning Power The...

Continue Reading
Deckers Outdoor Achieves Record Stock Price Amid Growth

Updated Category News Views 253

Deckers Outdoor Corporation Reaches New Stock Milestone Deckers Outdoor Corporation (NYSE: DECK), known for its exceptional footwear and apparel offerings, has achieved a remarkable milestone as its stock price climbs to an all-time high of $213.03. This impressive rise is indicative of the company's strong financial health and robust market performance. With a...

Continue Reading
Remarkable Growth in Badger Meter's Financial Performance

Updated Category News Views 76

Badger Meter's Impressive Q3 2024 Financial Results Badger Meter, Inc. (NYSE: BMI) has recently reported its remarkable financial outcomes for the third quarter that ended on September 30, 2024. The company has recorded impressive growth across its various financial metrics, indicating strong market demand and operational excellence. Key Highlights of Q3 2024 The latest...

Continue Reading
Perion Network's Collaboration with Experian Boosts Ad Targeting

Updated Category News Views 242

Perion Network Partners with Experian to Enhance Ad Solutions Perion Network (NASDAQ: PERI), a leading figure in the digital advertising technology sector, is taking a significant step forward with its collaboration with Experian, a renowned global data and analytics company. This strategic partnership aims to enhance Perion's advertising capabilities, focusing on...

Continue Reading
Novo Nordisk Investors Seek Class Action Guidance Following Lawsuit

Updated Category News Views 213

Insights into the Novo Nordisk Class Action Lawsuit Recent news has surfaced regarding Novo Nordisk A/S (NYSE: NVO), a major player in the global pharmaceutical industry, which is making headlines following the announcement of a class action lawsuit. This legal action is spearheaded by Berger Montague, a notable law firm based in various cities across the United States,...

Continue Reading